In the Media

InMed Shares Preclinical Data at 2020 EB World Congress

At the EB World Congress in London, UK, InMed’s scientific team officially revealed CBN as the active pharmaceutical ingredient (API) in INM-755 while exhibiting preclinical data in support of the INM-755 program in epidermolysis bullosa (EB).

InMed’s scientific posters from EB World Congress can be viewed here.

Share this post

Latest Media News